Viewing entries in
Highlights

Marsala Biotech Engages Evolution Life Science Partners

MARSALA BIOTECH ENGAGES EVOLUTION LIFE SCIENCE PARTNERS TO PROVIDE FINANCIAL AND STRATEGIC ADVISORY SERVICES

Winnipeg, Manitoba, October 3, 2016 — Marsala Biotech Inc. (“Marsala Biotech” or the “Company”), a drug discovery and development company providing innovative solutions for the treatment of cancer, today announced that it has engaged Gordian Investments LLC through its division, EVOLUTION Life Science Partners, a leading investment banking, securities and investment management firm, to provide strategic corporate advisory and investment banking services to the Company. EVOLUTION will focus on identifying, evaluating and pursuing alternative strategies to maximize shareholder value through its full scope of investment banking services.

“Engaging EVOLUTION will enable the strategic positioning of Marsala Biotech, which in turn will increase its ability to reach those patients who will benefit from its innovative anti-cancer approaches,” said Marsala Biotech’s Chief Executive Officer, Dr. George Thomas.

David Parke, Managing Director of EVOLUTION commented, "We are delighted to partner with Marsala Biotech in the financial and value creation components of its corporate strategy through our full-service investment banking capabilities. We are looking forward to working with Dr. Thomas and his team to assist with strategic planning, developing strategic partnerships, advising on potential transactions and introducing the company to the investment community."

ABOUT EVOLUTION 

EVOLUTION, founded by Frederick Frank and Mary Tanner in 2014, is an investment bank focused on the needs of life sciences and healthcare companies.  Through Gordian Investments, LLC, (member: FINRA/SIPC) EVOLUTION assists companies throughout their life cycle, including capital raising, licensing/partnering, and M&A.  The senior bankers at EVOLUTION have an average of 25 Years of investment banking and industry experience, executing hundreds of M&A, partnering and capital raising engagements, with an aggregate deal value in excess of $125 Billion.  EVOLUTION is based in San Francisco, CA and New York, NY. Gordian Investments is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA) To learn more about Gordian Investments and EVOLUTION, visit http://evolutionlsp.com

ABOUT MARSALA BIOTECH, INC.

Marsala Biotech Inc. is a drug discovery and development company, concentrating on innovative treatments for cancer. To learn more about Marsala Biotech, visit http://marsalabiotech.com/

NIH RAC Review for E10A Completed

Marsala Biotech successfully completes the National Institutes of Health – Recombinant DNA Advisory committee (NIH-RAC) review on its planned clinical trial of E10A in Head and Neck Cancer patients.

Marsala Receives Manitoba CSB Grant

Marsala Biotech receives funding from the Manitoba Commercialization Support for Business (CSB) grant to support development and commercialization of its lead technology E10A.

NRC Funding for E10A Development

Marsala Biotech receives financial contribution from the National Research Council of Canada for the development of E10A.